Posted by Michael Wonder on 16 Aug 2019
EMA/FDA analysis shows high degree of alignment in marketing application decisions between EU and US
16 August 2019 - EMA and the US FDA are aligned in more than 90% of marketing authorisation decisions for new medicines.
This is one of the findings of a joint EMA/FDA analysis comparing decisions on 107 new medicine applications at the two agencies between 2014 and 2016. The study also looked at applications for which the agencies had differing outcomes in terms of type of approval and indication.
The most common reason for diverging decisions at the two agencies were differences in conclusions about efficacy. Differences in clinical data submitted in support of an application were the second most common root of divergent FDA and EMA decisions.
